Systemic sclerosis (SSc; scleroderma) is a connective tissue disease, characterized by fibrotic, immunological, and vascular abnormalities. Interleukin-10 (IL-10) is an anti-inflammatory cytokine that modulates collagen production and B-cell survival. To determine if certain IL-10 genotypes are risk factors for the development of SSc and influence disease-associated autoimmune responses, 248 Caucasian and 264 Japanese SSc patients and controls were genotyped for three loci: À3575, À2849, and À2763. Sera from patients were characterized for SSc-associated autoantibodies. In Caucasians, at À3575 and À2763, the frequency of AA homozygotes was higher in patients as compared with controls (P ¼ 0.0005; P ¼ 0.002). In Japanese subjects, the frequency of AC heterozygotes at À2763 was higher, and that of CC homozygotes lower, in patients with diffuse SSc as compared to controls (P ¼ 0.04). Particular IL-10 genotypes were associated with SSc-related autoantibodies. These results suggest that IL-10 genotypes contribute to the etiology of scleroderma.
Interleukin-10 (IL-10) is a pleiotropic cytokine produced primarily by monocytes, T cells, and B cells. IL-10 has both activating and inhibitory influences on T cells, is involved in immunoglobulin class switching, and promotes B-cell survival. 1 Additionally, IL-10 modulates the extracellular matrix by inhibiting fibroblast proliferation and collagen production. 2, 3 The interindividual differences in IL-10 production levels have a large genetic component. [4] [5] [6] Owing to these properties, there is a growing interest in determining the role of IL-10 genes in autoimmune diseases. 7 Scleroderma is an autoimmune rheumatic disease characterized by extensive fibrosis, thickened skin, vascular alterations, and immunological abnormalities. There are two major subtypes of systemic sclerosis (SSc). 8 Diffuse SSc is the most serious form, characterized by extensive fibrosis of skin and internal organs; development of the disease can be rapid and severe. Limited SSc is a milder disease form, as patients have less involvement of internal organs and slower disease progression. The majority of SSc patients produce antibodies directed at nuclear antigens, which are strongly associated with organ involvement and disease outcome. [9] [10] [11] [12] Although the etiology of SSc is unknown, genetic factors are thought to be important. Several polymorphic genes-which are either risk factors for the development of SSc or influence disease-associated autoimmune responsiveness-have been identified. These include human leukocyte antigens (HLA), fibrillin-1, and GM and KM allotypes-genetic markers of g and k chains, respectively. [13] [14] [15] To determine if allelic variation at IL-10 loci is associated with SSc and SSc-related humoral autoimmune responses, DNA samples from Caucasian and Japanese patients and controls were genotyped at three IL-10 sites (À3575, À2849, and À2763) and patients' sera were characterized for disease-related autoantibodies.
This study was approved by the Institutional Review Board/Ethical Committee for human research of the Medical University of South Carolina and the Keio University School of Medicine. All subjects provided their written informed consent. Caucasian subjects consisted of 105 SSc patients (67 limited, 38 diffuse) and 143 controls presenting at the Rheumatology Clinic of the Medical University of South Carolina. Controls consisted of unrelated patients with osteoarthritis, fibromyalgia, gout, or regional musculoskeletal pain syndromes. Controls with conditions associated with autoimmune or connective tissue diseases were excluded. Japanese subjects consisted of 127 SSc patients (86 limited, 41 diffuse) presenting at Keio University School of Medicine and 137 healthy, ethnically matched controls living in the Tokyo area. All patients fulfilled the American College of Rheumatology criteria for SSc. 16 Genomic DNA samples were genotyped by PCR-restriction fragment length polymorphism methods. The method for genotyping at À3575 was modified from Moraes et al. 17 A 228 base pair (bp) sequence containing the À3575 single-nucleotide polymorphism (SNP) was amplified (F 5 0 -GGT TTT CCT TCA TTT GCA GC-3 0 and R 5 0 -ACA CTG TGA GCT TCT TGA GG-3 0 ) and digested with the restriction enzyme Tsp509I, which cuts this product into 121 and 107 bp pieces in the presence of the T allele. Genotypes at positions À2849 and À2763 were determined using the same primer set (F 5 0 -ACA TTT CAG AAC AAA TAA AGA AGT CAG-3 0 and R 5 0 -GTG CAG TGG CAT GAT CTC AG-3 0 ) to amplify a 300 bp product including both SNPs. Digestion with AlwI results in products of 202, 77, and 21 bp for the G allele, and products of 279 and 21 bp, if the A allele is present at position À2849. Digestion with Tsp509I results in products of 174 and 126 bp, if the A allele is present at position À2763; no digestion of the 300 bp amplified product occurs in the presence of the C allele. Indirect immunofluorescence (anticentromere (ACA)), double immunodiffusion and protein immunoprecipitation (anti-topoisomerase I (topo I)), and immunoprecipitation (anti-RNA polymerase I/III (RNAP) and U1 ribonucleoprotein (U1 RNP)) assays were used to identify autoantibodies in patients' sera, as described previously. 12 The distribution of genotype frequencies was analyzed using Pearson's w 2 test, except when cell counts were less than or equal to 5; in the latter case, data were analyzed by Fisher's two-tailed exact test. Statistical significance was defined as Po0.05. Odds ratio (OR) was calculated to measure the strength of the associations observed. When cell counts were less than or equal to 5, no ORs were determined, as the use of large sample theory to calculate confidence intervals for the ORs can only be justified when all of the expected cell counts are greater than 5.
The distribution of IL-10 genotypes and prevalence of autoantibodies in Caucasian subjects is presented in Table 1 . At À3575 and À2763, the frequency of AA homozygotes was significantly higher in patients as compared with controls (29.5 vs 11.8%, P ¼ 0.0005, OR ¼ 3.1, CI 1.6-5.9; 20.6 vs 7.2%, P ¼ 0.002, OR ¼ 3.3, CI 1.5-7.5). At position À2849, the frequency of GG homozygotes was significantly lower in patients as compared to controls (44.2 vs 57.4%, P ¼ 0.04, OR ¼ 0.59, CI 0.35-0.98). Subdivision of the patient population showed that subjects with the limited form of the disease were the primary contributors to the overall variation at À3575 and À2849. Compared to controls, the frequency of AA homozygotes (À3575) was increased (33 vs 11.8%, P ¼ 0.0002, OR ¼ 3.6, CI 1.76-7.43), while that of GG (À2849) was decreased (41.8 vs 57.4%, P ¼ 0.03, OR ¼ 0.53, CI 0.29-0.96) in patients with limited SSc. At À2763, however, subjects in both disease categories contributed to the overall variation. Compared to controls, the frequency of AA homozygotes was higher in both limited and diffuse SSc (21 vs 7.2%, P ¼ 0.003, OR ¼ 3.5, CI 1.48-8.48; 19 vs 7.2%, P ¼ 0.03, OR ¼ 3.0, CI 1.06-8.55). The frequency of the AC genotype at this locus was significantly lower in patients As autoantibodies in SSc are associated with disease subgroup and prognostic factors, we analyzed the distribution of IL-10 genotypes among patients with and without disease-associated autoantibodies. The distribution of IL-10 genotypes was significantly different between Caucasian patients positive for antibodies to RNAP and U1 RNP compared to those without these autoantibodies (Table 1 ). At À3575 in SSc patients as a whole, the frequency of TT homozygotes was higher in subjects with antibodies to RNAP compared to those without these antibodies (60 vs 27.1%, P ¼ 0.005, OR ¼ 4.0, CI 1.46-11.15); this was primarily due to an increased frequency of this genotype in diffuse patients positive for the antibody (58.8 vs 19%, P ¼ 0.02). The frequency of GG homozygotes at À2849 and that of CC at À2763 was higher in patients with anti-RNAP antibodies compared to those without these autoantibodies (65 vs 39.3%, P ¼ 0.03, OR ¼ 2.8, CI 1.03-7.94; 70 vs 34.1% P ¼ 0.003, OR ¼ 4.5, CI 1.5-12.9). In subjects with antibodies to U1 RNP, the frequency of the À2763 CC genotype was lower than in those without these autoantibodies (10 vs 44.5%, P ¼ 0.04). IL-10 genotypes were not associated with anti-topo I or ACA (data not shown).
The distribution of IL-10 genotypes in Japanese SSc patients and controls, and in SSc patients with and without ACA, U1 RNP, and topo I autoantibodies is presented in Table 2 . Interestingly, no subjects had the AA genotype at any loci. Examination of the patient population as a whole showed no significant difference in genotype frequencies between patients and controls. Subgroup analysis, however, revealed that in diffuse patients at À2763, the frequency of AC heterozygotes was higher (21 vs 8.6%, P ¼ 0.04, OR ¼ 2.8, CI 1.02-7.79) and that of CC homozygotes lower (79 vs 91.4%, P ¼ 0.04, OR ¼ 0.35, CI 0.13-0.97) than the respective frequencies in the control population.
In the total patient population, the frequency of AT heterozygotes at À3575 was higher (20.8 vs 6.8%, P ¼ 0.03, OR ¼ 3.6, CI 1.04-12.58) and that of TT homozygotes lower (79.2 vs 93.2%, P ¼ 0.03, OR ¼ 0.27, CI 0.08-0.97) in patients with ACA than in those without these autoantibodies. Patients with limited SSc accounted for the increased frequency of the AT genotype in ACApositive subjects (20.8 vs 3.2%, P ¼ 0.02). The AT heterozygotes at this locus were also more prevalent in the diffuse SSc patients with anti-U1 RNP antibodies than in those lacking these autoantibodies (75 vs 5.4%, P ¼ 0.004). At À2763, the frequency of AC heterozygotes was higher (24.1 vs 6.1%) and that of CC homozygotes lower (75.9 vs 93.9%) in patients with antibodies to topo I than in those without these autoantibodies (P ¼ 0.005). Patients with limited SSc were primarily responsible for the increased frequency of AC heterozygotes in anti-topo I-positive subjects (22.6 vs 5.5%, P ¼ 0.03). IL-10 genotypes were not associated with antibodies to RNAP. Other genotype frequencies were similar between total patients or subgroups and controls (data not shown).
In Caucasians, homozygosity for the A allele at À3575 and À2763 was associated with over three-fold higher risk of developing SSc. The protective effects of IL-10 against fibrosis, a hallmark feature of scleroderma, could contribute to the immunological mechanisms underlying these associations. IL-10 reduces tumor necrosis factor-a (TNF-a)-induced proliferation of fibroblasts and decreases production of type 1 collagen and fibronectin by fibroblasts. 2, 3 As mentioned before, the quantitative expression of IL-10 is highly heritable, and IL-10 genotypes contribute to this phenomenon. Indeed, the risk-conferring genotypes in Caucasians in this study-AA (À3575) and AA (À2763)-are strongly associated with low production of this cytokine. 6 In the Japanese subjects, there were no AA homozygotes and the only genotype at À2763 carrying the A allele, the AC heterozygote, was associated with over two-fold increased risk of diffuse SSc. Thus, in these A allele carrying subjects, the IL-10 levels may be too low to afford protection from fibrosis, resulting in a higher risk of developing scleroderma. Homozygosity for the G allele at À2849 was marginally associated with protection from the disease in Caucasians, which is in line with the reported over-representation (although not statistically significant) of this allele in IL-10 high producers. 6 Since fibrosis is more extensive in patients with diffuse SSc than limited SSc, in our subgroup analyses we had expected the diffuse patients to account for most of the variation observed in the total patient population. This appears to be the case for the Japanese subjects, where the frequency of AC heterozygotes was higher in diffuse, but not in limited, patients than that in the controls. In Caucasians, however, patients from both categories contributed to the overall variation at À2763, while those with the limited form of the disease were the primary contributors to the differences at À3575 and À2849 loci. Clearly, other factors, in addition to IL-10 genotypes, contribute to the clinical phenotype of SSc patients. The results presented here are at variance with those reported by Crilly et al, 18 who found no association between IL-10 genotypes and SSc as a whole, but reported a decreased frequency of a genotype associated with high IL-10 production in patients with the diffuse form of the disease. The two studies, however, are not comparable: Crilly et al studied the IL-10 sites in the proximal region of the promoter, whereas we examined distal SNPs. Other differences include the study population-homogeneous Scottish Caucasians in the study by Crilly et al vs heterogeneous North American Caucasians and homogeneous Japanese in the present study.
In addition to being risk factors for the development of the disease, particular genotypes in both Caucasian and Japanese populations contributed to disease-related autoantibodies associated with different clinical phenotypes of scleroderma. In Caucasian subjects, homozygosity for the T, G, and C alleles at À3575, À2849, À2763, respectively, was associated with the presence of anti-RNAP antibodies. At À3575, patients with the diffuse form of the disease contributed to this association; at the other two loci, no disease subtype-associated differences were found. In the Japanese patients, heterozygosity at À3575 was associated with the prevalence of ACA, while that at À2763 was associated with the presence of antitopo I antibodies. Patients with the limited form of the disease contributed to the variation at both loci.
Since this is the first study of this type for scleroderma, these results cannot be compared directly with other studies. Involvement of IL-10 genotypes in humoral immunity to autoantigens is in accord with the enhancing effect of this cytokine on B-cell survival. However, no consistent pattern of autoreactivity, explainable by the known associations between particular genotypes and the cytokine levels, emerges. It might be relevant to point out that the autoantibodies examined here are strongly associated with particular HLA alleles, and for ACA, a stronger association has been found with certain promoter region determinants of the TNF-a gene. 14, 19 Perhaps simultaneous examination of HLA, TNF-a and IL-10 loci in a large study population would shed further light on humoral autoreactivity in scleroderma.
The reason for the observed ethnic differences in genetic association is not clear. Genetic heterogeneity might in part explain the ethnic disparities observed here. 20 Differences in allele frequencies and linkage disequilibrium among populations originating from different continents may also contribute to ethnically restricted associations. 21 Additionally, the low frequency of A alleles in the Japanese subjects may have reduced the statistical power to detect an association between IL-10 genotypes and disease risk in this ethnic group. In addition to differences in allele frequencies between the groups, it is likely that multiple genes interact in an epistatic manner to cause SSc, and differences in gene frequencies at these loci result in differences in relative risk to develop the disease in different ethnic groups. Evidence for such epistatic interactions in SSc has been presented elsewhere. 15 In addition to the possible influence of IL-10 genes (via their gene products) on SSc pathogenesis discussed above, the observed associations could also be explained by linkage disequilibrium between the IL-10 alleles and those of another, as yet unidentified, locus for SSc. Such case-control studies cannot distinguish between the two possibilities. To our knowledge, this is the first report of an association between IL-10 genotypes and SSc-related autoimmune responses. Although some of the IL-10 genotype associations with SSc and SSc-related autoimmune responses reported here are highly significant and can, at least partially, be explained by the known immunological properties of IL-10, they must be followed by confirmation in an independent study population to be of wider significance.
